Despite Data Concerns, Panel Recommends First-In-Class Toe Implant
This article was originally published in The Gray Sheet
Executive Summary
Cartiva, a toe implant to treat osteoarthritis, received a strong recommendation from a panel of FDA experts despite suggestions that the device had not fully proven itself.
You may also be interested in...
Advisory Panel Recommends Approval For Link’s STAR Ankle Replacement
An FDA advisory panel recommended approval of Link Orthopedics' STAR ankle replacement system April 24 despite FDA reviewers' conclusion that results of the firm's pivotal trial are unclear
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.